When are BATTMAN trial results expected?

Agenus has not provided a specific timeline, but similar trials typically take two years or more.

Agenus' BATTMAN Phase III Trial: A Pivotal Test for BOT+BAL in mCRC

Q: What type of cancer does the BATTMAN trial target?

The BATTMAN trial targets microsatellite stable metastatic colorectal cancer (MSS mCRC), the most common form.

Agenus has launched the BATTMAN phase III trial to evaluate its BOT+BAL combination therapy in MSS metastatic colorectal cancer. The trial aims to confirm early survival signals observed in earlier studies.

June 5, 2026

1 min read

Source: Zacks

Agenus (ticker: AGEN) has announced the initiation of the BATTMAN phase III trial, a pivotal study evaluating its combination therapy BOT+BAL (botensilimab plus balstilimab) in patients with microsatellite stable metastatic colorectal cancer (MSS mCRC).

Trial Details

The BATTMAN trial is a randomized, multicenter study comparing BOT+BAL against standard chemotherapy in MSS mCRC patients who have progressed on prior therapies. The primary endpoint is overall survival.

Context

MSS mCRC accounts for approximately 95% of metastatic colorectal cancer cases and is typically unresponsive to current immunotherapies. Promising response rates from phase II data have prompted this phase III confirmation.

What It Means for Investors

Success of the BATTMAN trial could unlock a large market for Agenus and potentially change treatment paradigms. Conversely, failure would significantly damage the company's prospects. Investors await results expected within the next two years.

Frequently Asked Questions

BOT+BAL is a combination of two immunotherapies: botensilimab (anti-CTLA-4) and balstilimab (anti-PD-1), being tested for metastatic colorectal cancer.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.